journal article·2020-10-15Open access

Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma

Atsushi Hiraoka, Takashi Kumada

Applied Sciences· Volume 10· Issue 20

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. The selection of therapeutic modalities and the prognosis of affected patients are well known to be dependent not only on the tumor burden but also on the hepatic reserve function. Antiviral treatments for chronic hepatitis related to a viral infection and an increase in cases of nonviral HCC associated with the aging of society have resulted in dramatic changes regarding the characteristics of HCC patients. With recent developments in therapeutic modalities for HCC, a more detailed assessment of hepatic function has become an important need. Studies in which the relationship of albumin-bilirubin (ALBI) grade with the prognosis of HCC patients was investigated were reviewed in order to evaluate the usefulness of newly developed ALBI and modified ALBI (mALBI) grades for HCC treatment, as those scoring methods are considered helpful for predicting the prognosis and selecting therapeutic modalities based on the expected prognosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Hepatocellular Carcinoma Treatment and Prognosis · Hepatitis C virus research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Gastroenterology Center, Ehime Prefectural Central Hospital, Kasuga-cho 83, Ehime 790-0024, Japan

Department of Nursing, Gifu Kyoritsu University, Gifu 503-8550, Japan

References (81)

Show source-provided references
1. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma10.1200/EDBK_200939 ↗
2. A global view of hepatocellular carcinoma: Trends, risk, prevention and management10.1038/s41575-019-0186-y ↗
3. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E ↗
4. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)10.1007/s005350300038 ↗
5. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score10.1002/hep.20486 ↗
6. Transection of the oesophagus for bleeding oesophageal varices10.1002/bjs.1800600817 ↗
7. Kokudo, N., Hasegawa, K., Akahane, M., Igaki, H., Izumi, N., Ichida, T., Uemoto, S., Kaneko, S., Kawasaki, S., and Ku, Y. (2015). Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol. Res., 45.10.1111/hepr.12464 ↗
8. Hepatocellular carcinoma10.1016/S0140-6736(18)30010-2 ↗
9. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions10.1055/s-0032-1329906 ↗
10. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi’s Subclassification (Kinki Criteria)10.1159/000439290 ↗
11. Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus10.1111/1753-0407.12340 ↗
12. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update10.1007/s00535-018-1532-5 ↗
13. Kumada, T., Toyoda, H., Tada, T., Yasuda, S., and Tanaka, J. (2020). Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer, 1–11.10.1159/000507933 ↗
14. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade10.1200/JCO.2014.57.9151 ↗
15. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications10.1159/000452846 ↗
16. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma10.1111/jgh.13291 ↗
17. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis10.1159/000488778 ↗
18. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function10.1159/000479984 ↗
19. Impact of Albumin-Bilirubin Score on Short- and Long-Term Survival After Living-Donor Liver Transplantation: A Retrospective Study10.1016/j.transproceed.2020.01.020 ↗
20. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis10.1056/NEJM199603143341104 ↗
21. An Albumin-Bilirubin (ALBI) Grade–based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria10.1097/COC.0000000000000581 ↗
22. The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma10.1002/jso.25721 ↗
23. Albumin-Bilirubin Score for Predicting Post-Transplant Complications Following Adult-to-Adult Living Donor Liver Transplantation10.12659/AOT.910824 ↗
24. Petrov, B.N., and Caski, F. (1973). Information theory as an extension of the maximum likelihood principle. Proceedings of the 2nd International Symposium on Information Theory, Springer.
25. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection10.1038/s41598-018-22923-4 ↗
26. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis10.7150/jca.21313 ↗
27. Post-operative albumin-bilirubin grade predicts long-term outcomes among Child–Pugh grade A patients with hepatocellular carcinoma after curative resection10.1016/j.hbpd.2018.07.011 ↗
28. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC10.1186/s12957-018-1500-9 ↗
29. A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients10.1159/000486590 ↗
30. Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy10.21037/atm.2019.06.01 ↗
31. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy10.1097/JCMA.0000000000000001 ↗
32. Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation10.1007/s10620-017-4775-8 ↗
33. Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation10.1038/s41598-018-19251-y ↗
34. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade
35. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial)10.1200/JCO.2019.37.15_suppl.4002 ↗
36. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma10.1016/j.surge.2017.07.003 ↗
37. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma
38. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases10.1159/000481242 ↗
39. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis10.1200/JCO.2018.36.15_suppl.4018 ↗
40. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan10.1159/000343875 ↗
41. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis10.1159/000480256 ↗
42. Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma10.1016/j.jvir.2018.06.016 ↗
43. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma10.1111/liv.14194 ↗
44. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade10.1159/000447061 ↗
45. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements10.1159/000507370 ↗
46. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: A secondary analysis of a phase III study10.1007/s00432-018-2610-z ↗
47. Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic10.1111/jgh.14564 ↗
48. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use10.1111/jgh.13783 ↗
49. Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma10.1007/s10637-015-0292-9 ↗
50. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients with Hepatocellular Carcinoma in Vietnam10.1177/1073274819865269 ↗
51. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial10.1016/S0140-6736(16)32453-9 ↗
52. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment10.1007/s10637-017-0507-3 ↗
53. Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy10.1111/hepr.13196 ↗
54. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment10.1159/000488453 ↗
55. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice10.1111/hepr.13180 ↗
56. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma10.1093/jjco/hyy153 ↗
57. Takada, H., Kurosaki, M., Tsuchiya, K., Komiyama, Y., Itakura, J., Takahashi, Y., Nakanishi, H., Yasui, Y., Tamaki, N., and Maeyashiki, C. (2019). Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers, 11.10.3390/cancers11091256 ↗
58. Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma10.21873/anticanres.14387 ↗
59. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial10.1016/S0140-6736(18)30207-1 ↗
60. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis10.1111/hepr.13243 ↗
61. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis10.1002/cam4.1909 ↗
62. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis10.1002/cam4.2241 ↗
63. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma10.1159/000501281 ↗
64. Fuchigami, A., Imai, Y., Uchida, Y., Uchiya, H., Fujii, Y., Nakazawa, M., Ando, S., Sugawara, K., Nakayama, N., and Tomiya, T. (2020). Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLoS ONE, 15.10.1371/journal.pone.0231427 ↗
65. Kaneko, S., Tsuchiya, K., Yasui, Y., Inada, K., Kirino, S., Yamashita, K., Osawa, L., Hayakawa, Y., Sekiguchi, S., and Higuchi, M. (2020). Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol. Res.10.1111/hepr.13567 ↗
66. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib10.1159/000503031 ↗
67. A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria10.1007/s10620-019-05813-1 ↗
68. The combination of the preoperative albumin-bilirubin grade and the fibrosis-4 index predicts the prognosis of patients with hepatocellular carcinoma after liver resection10.5582/bst.2019.01212 ↗
69. Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy10.1007/s11605-018-3810-1 ↗
70. Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection10.7150/jca.33877 ↗
71. (1989). Liver Cancer study Group of Japan the general rules for the clinical and pathological study of primary liver cancer. Surg. Today, 19, 98–129.10.1007/BF02471576 ↗
72. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma10.1111/jgh.13250 ↗
73. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma10.1002/ags3.12212 ↗
74. Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma10.1111/jgh.13312 ↗
75. Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma10.1111/jgh.13457 ↗
76. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy10.7150/jca.22925 ↗
77. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma10.4254/wjh.v11.i6.542 ↗
78. Albumin–Bilirubin and Platelet–Albumin–Bilirubin Grades Do Not Predict Survival After Transjugular Intrahepatic Portosystemic Shunt Creation10.1007/s00270-018-1923-2 ↗
79. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation10.1016/j.diii.2017.10.008 ↗
80. Child-Pugh, MELD, MELD-Na, and ALBI scores: Which liver function models best predicts prognosis for HCC patient with ascites?10.1080/00365521.2020.1788139 ↗
81. Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience10.1016/j.asjsur.2018.12.015 ↗